Trial Profile
A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and the Biological and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Mild to Moderate Alzheimer's Disease – a Pilot Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Sodium selenate (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- 06 Dec 2011 New trial record